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Gold nanomaterials are immerging candidates in medical diagnosis and treatment. Among them, gold nanorods (Au NRs) are 
widely used for cancer treatment. Tiopronin as a novel thiol drug was used to stabilize Au NRs in this work. Doxorubicin (DOX), 
a chemotherapeutic drug which works by interacting with DNA to arrest the cell cycle and induce apoptosis, was linked to Au 
NRs through electrostatic reaction with tiopronin, to obtain Au-TIOP-DOX NRs. Au NRs are also regarded as hyperthermia 
agents for photothermal cancer treatment. This delivery system (Au-TIOP-DOX NRs) was designed for passively targeting tumor 
cells in cancer therapy. More importantly, the carboxyl groups of tiopronin can be modified with some biological molecules 
(DNA/RNA, peptides, or drugs) to make Au NRs as a novel drug-delivery system for cancer treatment. 
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Gold nanorods (Au NRs) are promising nanomaterials as 
therapeutics, imaging probes, contrast agents and drug ve-
hicles in cancer treatment [1–4]. The unique properties, 
such as tunable surface plasmon resonance (SPR), two- 
photon luminescence and ease of functionalization, make 
them suitable in thermal therapy, cell imaging, gene silenc-
ing and targeted drug delivery [5–8]. PEGylated Au NRs 
are reported to be more stable in physiological condition 
and obtain a longer circulation time in vivo [9,10]. In addi-
tion, Dreaden et al. [11] synthesized a small molecule-   
Au NRs conjugate which can selectively target tumor-      
associated macrophage cells and induce cytotoxicity to 
breast cancer cells. 
Cetyltrimethylammonium bromide (CTAB), a cationic 
detergent, is used as stabilizer and surface coating in the 
preparation of Au NRs and it is highly toxic to cells. Due to 
the free CTAB in the Au NRs solution which can hardly be 
removed totally, the biological application of Au NRs is 
limited because of the cell toxicity [12,13]. Much work has 
been done to optimize the surface coating of Au NRs and 
then to reduce the cytotoxicity, improve the biocompatibil-
ity and increase the drug loading efficiency [14–16]. 
Among these work, PEGylation seems to be a good choice 
as it could prolong the circulation time of Au NRs in the 
circulatory system, escape from the clearance of reticulo-
endothelial system (RES) [17]. However, the cellular uptake 
of PEG-Au NRs is not that satisfactory to people’s expecta-
tion and we are looking for a better surface coating of Au 
NRs. In this work, we replace the CTAB on the Au NRs 
surface with tiopronin, a novel thiol-group drug which 
could form Au-S bond, a covalent bond stronger than the 
interaction between CTAB and Au atom. Thus, the re-
placement of CTAB is highly efficient and biocompatibility 
is improved. Tiopronin also has a carboxyl group which is 
capable of lots of chemical reactions; therefore, much ther-
apeutics can be loaded on Au NRs. Here, we functionalized 
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tiopronin-coated Au NRs with a clinical used cancer thera-
peutic, doxorubicin (DOX), and the treatment efficacy of 
Au-TIOP-DOX NRs were assessed initially [18,19].  
1  Materials and methods 
(i) Chemicals.  Gold chloride trihydrate (99.9%, 
HAuCl43H2O), cetyltrimethylammonium bromide (98%, 
CTAB, C19H42BrN) and N-(2-mercaptopropionyl) glycine 
(tiopronin, C5H9NO3S) were purchased from Sigma-Aldrich 
(St Louis, USA). L(+)-Ascorbic acid (99.0%) was supplied 
by Acros (USA). Sodium citrate (99.5%, C6H5Na3O72H2O) 
was obtained from Solarbio (Beijing, China). Silver nitrate 
(99.8%, AgNO3) was purchased from GuangFu (Tianjin, 
China). Doxorubicin (99%, DOX) was purchased from 
Zhejiang Hisun Pharmaceutical Co. Ltd. All glass wares 
used for the preparation and storage of gold nanoparticles 
were cleaned with aqua regia (HCl:HNO3 = 3:1, v:v). All 
chemicals were used without further purification and Mil-
li-Q water was used throughout this study.  
(ii) Synthesis of CTAB capped gold nanorods.  CTAB 
capped Au NRs (Au-CTAB NRs) were prepared according 
to the seed-mediated growth method [20]. Briefly, a seed 
solution was prepared by mixing 9.15 mL of CTAB (0.1 
mol/L) and 0.25 mL of HAuCl4 (0.01 mol/L) with 0.6 mL 
freshly prepared ice-cold NaBH4 solution (0.1 mol/L). The 
color of the solution changed from dark yellow to brownish 
yellow under vigorous stirring, indicating the formation of 
the seed solution. This seed solution was used within 2–6 h 
for the synthesis of the Au-CTAB NRs. Briefly, 28.27 mL 
of 0.1 mol/L CTAB was mixed with 1.2 mL of 0.01 mol/L 
HAuCl4 and 0.18 mL of 0.01 mol/L silver nitrate aqueous 
solution. After gentle mixing of the solution, 0.2 mL 0.1 
mol/L ascorbic acid was added, and then the solution 
changed to colorless transparent. With continuously stirring, 
0.15 mL of the seed solution was added to initiate the 
growth of the Au-CTAB NRs.  
(iii) Tiopronin coating of Au NRs.  A surface ligand 
exchange reaction was adopted to obtain tiopronin coating 
of Au NRs (Au-TIOP NRs). Briefly, 1 mL of Au-CTAB 
NRs was centrifuged at 9000 r/min for 10 min, and the pre-
cipitate was re-dispersed in 1 mL deionized water. Under 
vigorous stirring, 1 mL Au-CTAB NRs and 1 mL tiopronin 
solution (2 mg/mL) were mixed, sonicated for 60 s and 
stirred overnight at room temperature. The resulting Au 
NRs were then collected by centrifugation at 9000 r/min for 
15 min and the tiopronin coated Au NRs were obtained. 
(iv) Preparation of DOX-conjugated Au NRs.  DOX 
loading onto Au-TIOP NRs was done by simply mixing 1 
mL 0.5 mg/mL DOX with 1 mL Au-TIOP NRs. The result-
ing solution was kept stirring overnight at room temperature. 
Excess DOX molecules were removed by centrifugation at 
10000 r/min for 10 min. To evaluate the DOX-loading effi-
ciency, the content of the residual DOX in the supernatant 
was determined by UV-Vis measurements at 480 nm [18]. 
The DOX-loading efficiency was calculated by  
Loading efficiency (%)




      (1) 
(v) Cell culture.  The human breast cancer cell line 
MCF-7 was maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) with 10% fetal bovine serum in a humid-
ified atmosphere containing 5% CO2 at 37ºC.  
(vi) Cell viability assay.  3-(4,5-dimethylthiazol-2-yl)- 
2,5-diphenyltetrazolium bromide (MTT) assay was used to 
evaluate the viability of MCF-7 cells. MCF-7 cells were 
seeded in 96-well plate, and after 24 h, Au-TIOP-DOX NRs 
and free DOX were added at the concentration of 0.08, 0.4, 
2, 10 μg/mL based on DOX into the plate. As negative con-
trols, cells were cultured with Au-CTAB NRs and Au-TIOP 
NRs at the corresponding concentration of Au NRs with the 
Au-TIOP-DOX NRs added. Another 24 h later, 10 μL MTT 
solution was added per well, and after 4 h of incubation, 
formazan crystals were dissolved in 150 μL DMSO. The 
absorbance was measured at 570 nm with a reference 
wavelength of 630 nm using an Infinite M200 microplate 
reader (Tecan, Durham, NC, USA). 
(vii) Characterization.  Morphology characterization of 
the Au NRs was performed using a Tecnai G2 20 S-TWIN 
transmission electron microscope (TEM, Philips, Nether-
lands) with 200 kV acceleration voltage. Optical absorption 
spectra were measured with a Lambda 950 UV/Vis/NIR 
spectrophotometer (Perkin-Elmer, USA). Zeta potential 
distribution was determined by a Nano ZS Zetasizer (Mal-
vern, England). The concentration of gold was determined 
via an Optima 5300DV Inductively Coupled Plasma Optical 
Emission Spectrometer, or an ELAN DRC-e Inductively 
Coupled Plasma Mass Spectrometer (Perkin-Elmer). 
2  Results and discussion 
The preparation of DOX-conjugated Au NRs (Au-TIOP- 
DOX NRs) is shown in Figure 1. CTAB stabilized Au NRs 
(Au-CTAB NRs) with aspect ratios ~4 were prepared firstly 
using a seed-growth method, the most popular method for 
the synthesis of colloidal Au NRs [20]. Tiopronin stabilized 
Au NRs (Au-TIOP NRs) were obtained via a well-     
developed ligand exchange method [21]. As we all know, 
thiol group exchange is the most common way to replace 
the original capping molecules since the metal-sulfur bond 
is known to be the strongest bond compared to other general 
functional groups. Tiopronin is a thiol drug with good bio-
compatibility used to control the rate of cysteine precipita-
tion and excretion in the disease named cystinuria [22,23]. 
It is commonly used as a stabilizing agent for metal nano-
particles, as its thiol groups can bind to the surface of na-
noparticles, preventing aggregation and sedimentation  
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Figure 1  Illustration of the procedure for preparing the doxorubicin functionalized tiopronin-capped Au NRs. 
[24]. In this work, tiopronin not only makes Au NRs stable 
in various physiological relevant media but also makes the 
outside of the nanorods bearing carboxyl groups. The re-
sulting Au-TIOP NRs exhibited reversed surface charge and 
allowed for the electrostatic adsorption of DOX. 
As shown in Figure 2, the transmission electron micros-
copy (TEM) images showed Au NRs in each step with a 
uniform morphology with aspect ratios ~4. It is also found 
that compared with CTAB capped Au NRs, Au-TIOP NRs 
have no change on shape and size after ligand-exchange 
reaction. From the negative staining TEM images of 
Au-TIOP NRs and Au-TIOP-DOX NRs shown in Figure 3, 
after DOX absorption reaction, an about 2 nm thin coating 
can be seen around the surface of Au-TIOP-DOX. 
In order to confirm each step of the surface-modification 
of Au NRs, zeta potential study was conducted. As shown 
in Figure 4, the zeta potential value of the as-prepared 
Au-CTAB NRs is +30.5 mV. After ligand exchange reac-
tion with tiopronin, the value changes to 18.9 mV, indi-
cating the charge reverse of the Au NRs because of the free 
negatively charged carboxy groups of tiopronin exposed on  
 
 
Figure 2  TEM images of Au-CTAB NRs, Au-TIOP NRs and 
Au-TIOP-DOX NRs.  
 
Figure 3  Negative stained TEM images of Au-TIOP NRs and 
Au-TIOP-DOX NRs.  
the outside surface of Au NRs. The successful adsorption of 
DOX makes the zeta potential to a value of 3.6 mV. 
Meanwhile, the photos in Figure 4 showed the color change 
in each step of different capped Au NRs. Moreover, after 
DOX binding to Au-TIOP NRs, the zeta potential remains a 
little negative, which may diffuse more quickly and perform 
better when delivering drugs deep into tissues [25]. 
In addition, to further determine whether the Au-TIOP- 
DOX NRs is successfully obtained, the UV-Vis absorption 
spectra of Au NRs with different coatings in each step were 
carried out. Au NRs showed two absorption bands: a strong 
longitudinal band in the near-infrared region corresponding 
to electron oscillation along the long axis and a weak trans-
verse band, similar to that of gold nanospheres, in the visi-
ble region corresponding to electron oscillations along the 
short axis [26–28]. Compared with CTAB capped Au NRs, 
the absorption peak of Au-TIOP NRs shifted from 734 to 
744 nm as shown in Figure 5. After electrostatic adsorption 
of DOX, Au-TIOP-DOX NRs showed two absorption peaks 
at 480 and 760 nm; 480 nm is the absorption peak of free 
DOX, and this demonstrated the attachment of DOX on the 
surface of Au-TIOP NRs. Because of the absorbance at 480 
nm, Au-TIOP-DOX NRs can be utilized as fluorescence 
probe for imaging. Current plasmonic nanoparticles for  
 
 
Figure 4  Zeta potential of Au-CTAB NRs, Au-TIOP NRs and 
Au-TIOP-DOX NRs. Corresponding pictures were shown on or under the 
zeta potential columns.  
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Figure 5  UV-Vis absorption spectra of Au-CTAB NRs, Au-TIOP NRs, 
Au-TIOP-DOX NRs and free DOX.  
photothermal therapy of cancer are gold nanospheres, na-
norods, nanoshells, and nanocages [3]. The last three types 
of plasmonic nanoparticles are more popular as they absorb 
light in the NIR window (650–900 nm [29]) where light 
penetration is optimal due to the minimal absorption by 
water and hemoglobin in the tissue. For their facile synthe-
sis, excellent stability, small size, high photothermal con-
version efficiency and tunable absorption in the biological 
window, Au NRs have become one of the most favorite 
nanoparticles for photothermal therapy. As UV-Vis absorp-
tion spectra shown in Figure 5, Au-TIOP-DOX NRs have a 
strong longitudinal band in the near-infrared region, so they 
also meet the conditions used for photothermal therapy.  
In order to ensure sufficient DOX-loading onto the sur-
face of gold nanorods by electrostatic adsorption, excess of 
DOX was added into the reaction. To evaluate the 
DOX-loading efficiency, the content of the residual DOX in 
the supernatant was determined by UV-Vis measurements 
at 480 nm [18]. The DOX-loading efficiency was calculated 
by eq. (1) is about 20% and the DOX-loading concentration 
is about 130 μg/mL. 
To evaluate the cell toxicity of each different capped Au 
NRs, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte trazolium 
bromide (MTT) assay was used to measure the cell viability 
after incubation with these nanomaterials. As shown in Fig-
ure 6, MCF-7 cells were cultured with Au-CTAB NRs, 
Au-TIOP NRs, Au-TIOP-DOX NRs and free DOX at dif-
ferent concentrations. The results showed that the cytotoxi-
city of Au-TIOP NRs is the lowest one, indicating the suc-
cessful exchange of CTAB. Due to the free CTAB in the Au 
NRs solution which can hardly be removed totally, the 
Au-CTAB NRs had relatively stronge cell toxicity. The 
toxicity test indicated the replacement of CTAB was highly 
efficient. Compared with DOX, the Au-TIOP-DOX NRs 
had a better effect in killing cancer cells from the cell via-
bility test. The high cytotoxic effect of Au-TIOP-DOX NRs 
is considered as a result of the release of DOX into MCF-7  
 
Figure 6  Cell viability of MCF-7 cells after 24 h treatment.  
cells after the cellular uptake. Hence, we expect that 
Au-TIOP-DOX NRs have promising potential as drug 
loading and delivery carriers in cancer therapy. 
3  Conclusions 
In summary, Au-TIOP-DOX NRs were prepared through 
thiol exchange and electrostatic adsorption method. Tiopro-
nin, a thiol drug with good biocompatibility, was used to 
replace the CTAB on the surface of Au NRs, and the re-
versed surface charge of Au-TIOP NRs allowed for the fur-
ther electrostatic adsorption of DOX. Characterizations 
were carried out to verify each step of different coatings of 
Au NRs. Furthermore, the cell viability was tested to deter-
mine the cancer-killing effect and the result was that the 
Au-TIOP-DOX NRs have a better cytotoxicity compared to 
free DOX. More importantly, the carboxyl groups of ti-
opronin not only can be used for electrostatic adsorption but 
also can be modified with molecules, peptides or drugs for 
active targeting purposes. The prepared doxorubicin func-
tionalized tiopronin-capped Au NRs can be promising in 
drug-delivery, fluorescence imaging and localized hyper-
thermia probe for cancer therapy. 
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